Research Studies and Clinical Trials Search
Results
Chronic Kidney Disease (CKD) and Proteinuria: A study on finerenone treatment for CKD and proteinuria
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with...
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria.
CKD stages 3–4 (decreased kidney function): A study of an oral medication called ferric citrate.
This study is being done for children: • Age 6-18 years old • Diagnosed with CKD stages 3–4 • age-appropriate normal serum phosphate levels...
This study is being done for children: • Age 6-18 years old • Diagnosed with CKD stages 3–4 • age-appropriate normal serum phosphate levels. The purpose of this study is to determine how well ferric citrate (Oral medication) will lower the level of FGF23 (a hormone that regulates phosphate levels in the blood), maintain or correct anemia and iron levels in the blood, and maintain normal levels of serum phosphate in children with CKD stages 3 and 4, that is, between 15% and 60% of normal function. CKD is a condition in which kidney function is decreased.
Focal Segmental Glomerulosclerosis (FSGS): A study of a medication called DMX 200 (repagermanium)
This study is being done for patients: • 18 and 80 years of age • Diagnosed with focal segmental glomerulosclerosis (FSGS)...
This study is being done for patients: • 18 and 80 years of age • Diagnosed with focal segmental glomerulosclerosis (FSGS). • Have been taking an ARB before the start of the study or are willing to start ARB treatment The main purpose of this study is to see if the medication DMX-200 (repagermanium) reduces protein from the blood to collect in the urine (proteinuria) and slows the loss of kidney function when taken at the same time as the drugs called angiotensin II receptor blockers (ARB) that work by reducing blood pressure and improving kidney function.
Hemodialysis Registry: A tool used to collect health information on children receiving hemodialysis for future research
The purpose of this research study is to continuously monitor outcomes in children around the world that are on hemodialysis. This registry should provide much needed information to doctors, nurses, dieticians, psychologists, social workers, and health care administrators, and...
The purpose of this research study is to continuously monitor outcomes in children around the world that are on hemodialysis. This registry should provide much needed information to doctors, nurses, dieticians, psychologists, social workers, and health care administrators, and help improve the wellbeing of children currently on HD. Being in this study involves having data collected from the child's medical record by a study team member and entered into an international database (registry). The data to be entered will include the child's date of birth, a unique study number, dates of service, and relevant medical information.
Nephrotic Syndrome Registry: A tool used to collect health information and laboratory samples to learn more about kidney diseases
Childhood onset nephrotic syndrome is a condition which affects the kidneys, causing them to leak protein from the blood into the urine. Nephrotic syndrome is a disease that can improve (remission) and worsen (relapse) at different times throughout childhood. NEPTUNE is a large...
Childhood onset nephrotic syndrome is a condition which affects the kidneys, causing them to leak protein from the blood into the urine. Nephrotic syndrome is a disease that can improve (remission) and worsen (relapse) at different times throughout childhood. NEPTUNE is a large North American study consisting of over 500 individuals and more than 5 years of research. By collecting health information and laboratory samples, our goal is to learn more about these kidney diseases and find better ways to prevent and treat people with nephrotic syndrome. New knowledge will be shared with researchers and the public.
Polycystic Kidney Disease (PKD): Blood, urine, and information collected and stored for research on better understanding PKD
This study is for ages 4-18. EPOC is an observational cohort of young patients with early ADPKD. A repository or biological samples and kidney imaging from these patients will be made available to the PKD research community to discover new prognostic biomarkers. Children...
This study is for ages 4-18. EPOC is an observational cohort of young patients with early ADPKD. A repository or biological samples and kidney imaging from these patients will be made available to the PKD research community to discover new prognostic biomarkers. Children diagnosed with PKD and undiagnosed siblings of PKD participants may be enrolled
Secondary hyperparathyroidism (SHPT): A study of the tolerance and safety of a medicine called etelcalcetide.
This study is being done for children: • 28 days to < 18 Years of age • Diagnosed with Hyperparathyroidism and Chronic Kidney Disease, receiving maintenance Hemodialysis...
This study is being done for children: • 28 days to < 18 Years of age • Diagnosed with Hyperparathyroidism and Chronic Kidney Disease, receiving maintenance Hemodialysis. Secondary hyperparathyroidism (SHPT) is a condition that is characterized by too much parathyroid hormone (PTH) being produced by the parathyroid glands. "Secondary" means that the hyperparathyroidism (HPT) is caused by another condition (for example, kidney disease). Secondary HPT is associated with loss of calcium from the bones, which can lead to bone pain and fractures, and problems with blood and heart vessels. The purpose of this study is to find out more about etelcalcetide in children with SHPT.